Zimmer Partners’s Immunocore IMCR Stock Holding History

Zimmer Partners’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,900	Closed	-$1.02M	–	144
2023 Q4	$1.02M	Sell	14,900 -20,700	-58%	-$1.08M	0.04%	93
2023 Q3	$1.85M	Hold	35,600	–	–	0.05%	103
2023 Q2	$2.13M	Buy	+35,600	New	+$2.03M	0.05%	90
2021 Q2	–	Sell	-10,000	Closed	-$426K	–	194
2021 Q1	$426K	Buy	+10,000	New	+$445K	0.01%	159

Other funds holding IMCR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Zimmer Partners's IMCR Position: Q1 2024 in Review

Zimmer Partners sold out of Immunocore (IMCR) in Q1 2024, closing a stake of 14,900 shares — an estimated $1.02M sold.

Zimmer Partners first reported a position in IMCR in Q1 2021 and held it in 4 quarters. The position peaked at $2.13M in Q2 2023. 149 funds tracked by Wall St. Rank hold IMCR as of Q1 2024.

Zimmer Partners reported no remaining Immunocore position as of Q1 2024 after selling out during the quarter.
Zimmer Partners sold 14,900 Immunocore shares in Q1 2024, an estimated $1.02M.
Zimmer Partners first reported a position in Immunocore in Q1 2021 and held it in 4 quarters.
Zimmer Partners's Immunocore position peaked at $2.13M in Q2 2023.
149 funds tracked by Wall St. Rank held Immunocore as of Q1 2024.

Based on Zimmer Partners's 13F filing for Q1 2024, filed 15 May 2024.